These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 24619298

  • 1. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.
    Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G.
    BMC Cancer; 2014 Dec 11; 14():937. PubMed ID: 25494701
    [Abstract] [Full Text] [Related]

  • 3. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.
    Jpn J Clin Oncol; 2015 May 11; 45(5):422-6. PubMed ID: 25670764
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.
    Gynecol Oncol; 2012 Sep 11; 126(3):369-74. PubMed ID: 22659190
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T, Asna N, Veizman A, Shpigel S, Matcejevsky D, Inbar M, Grisaru D.
    Anticancer Drugs; 2014 Mar 11; 25(3):340-5. PubMed ID: 24185383
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
    Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA.
    Lancet; 2019 Dec 07; 394(10214):2084-2095. PubMed ID: 31791688
    [Abstract] [Full Text] [Related]

  • 12. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL.
    Gynecol Oncol; 2013 Jun 07; 129(3):452-8. PubMed ID: 23474348
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Hagemann AR, Novetsky AP, Zighelboim I, Gao F, Massad LS, Thaker PH, Powell MA, Mutch DG, Wright JD.
    Gynecol Oncol; 2013 Dec 07; 131(3):535-40. PubMed ID: 24096113
    [Abstract] [Full Text] [Related]

  • 15. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR.
    J Clin Oncol; 2012 Jun 10; 30(17):2039-45. PubMed ID: 22529265
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.
    J Clin Oncol; 2008 Dec 10; 26(35):5761-6. PubMed ID: 19001330
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
    Markman M, Glass T, Smith HO, Hatch KD, Weiss GR, Taylor SA, Goodwin JW, Alberts DS.
    Gynecol Oncol; 2003 Mar 10; 88(3):282-8. PubMed ID: 12648576
    [Abstract] [Full Text] [Related]

  • 18. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S.
    BioDrugs; 2013 Aug 10; 27(4):375-92. PubMed ID: 23728884
    [Abstract] [Full Text] [Related]

  • 19. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
    Shawky H, Tawfik H, Hewidy M.
    J Egypt Natl Canc Inst; 2014 Sep 10; 26(3):139-45. PubMed ID: 25150129
    [Abstract] [Full Text] [Related]

  • 20. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Arimoto T, Nakagawa S, Oda K, Kawana K, Yasugi T, Taketani Y.
    Med Oncol; 2012 Jun 10; 29(2):1253-4. PubMed ID: 21380784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.